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Abstract
Background: Coronary artery disease (CAD) affects milions of people and can result in myocardial 
infarction (MI). Previously, mast cells (MC) have been extensively investigated in the context of hyper-
sensitivity, however as regulators of the local inflammatory response they can potentially contribute to 
CAD and/or its progression. The aim of the study was to assess if serum concentration of MC proteases: 
carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI.
Methods: The 44 patients with angiographically confirmed CAD (23 subjects with non-ST-segment 
elevation MI [NSTEMI] and 21 with stable CAD) were analyzed. Clinical data were obtained as well 
serum concentrations of carboxypeptidase A3, cathepsin G and chymase 1 were also measured.
Results: Patients with single vessel CAD had higher serum concentration of carboxypeptidase than 
those with more advanced CAD (3838.6 ± 1083.1 pg/mL vs. 2715.6 ± 442.5 pg/mL; p = 0.02). There 
were no significant differences in levels of any protease between patients with stable CAD and those with 
NSTEMI. Patients with hypertension had ≈2-fold lower serum levels of cathepsin G than normotensive 
individuals (4.6 ± 0.9 pg/mL vs. 9.4 ± 5.8 pg/mL; p = 0.001). Cathepsin G levels were also decreased 
in sera of the current smokers as compared with non-smokers (3.1 ± 1.2 ng/mL vs. 5.8 ± 1.2 ng/mL, 
p = 0.02). 
Conclusions: Decreased serum level of carboxypeptidase is a hallmark of more advanced CAD. Lower 
serum levels of carboxypeptidase A3 and catepsin G are associated with risk factors of blood vessel dam-
age suggesting a protective role of these enzymes in CAD. (Cardiol J 2019; 26, 6: 680–686)
Key words: mast cells, carboxypeptidase A3, cathepsin G, chymase 1, coronary artery 
disease
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Introduction
Chronic inflammation plays an important role 
in the pathogenesis of coronary artery disease 
(CAD) and acute myocardial infarction (AMI).The 
link between mast cell (MC) proteases and a lo-
cal inflammation process is an attractive research 
area. After activation, MC releases a wide range 
of proteases that have a potential pro or anti-
inflammatory effect [1–3]. The major MC proteases 
include tryptase, chymase 1, carboxypeptidase A3 
and cathepsin G.
In previously published work, it was shown 
that tryptase and endothelin-1 released from ac-
tivated MC are elevated in patients with an AMI 
[4]. Therefore, in the current study theaim was to 
analyze if other MC proteases chymase 1, carboxy-
peptidase A3 and cathepsin G play also have a role 
in CAD and AMI.
Chymase 1 is a serine protease stored in MC. 
It is released after stimulation during an inflamma-
tory or ischemic injury that is known to be a hall-
mark of AMI. The protein release is associated with 
activation of matrix metalloproteinase-9, which was 
shown to increase infarct size in an experimental 
model [5]. Oyamada et al. [6] have shown, that 
chymase 1 inhibition results in myocardial protec-
tion and attenuates fibrosis after AMI. In addition, 
chymase plays a crucial role in transformation of 
angiotensin I to angiotensin II independent from 
angiotensin converting enzyme [7].
Cathepsin G is a serine protease also synthe-
sized and stored in MC. However, MC are not the 
only source of the enzyme, it is also released from 
activated neutrophils and macrophages [8–10]. 
Despite that cathepsin G may promote early 
atherogenesis as it is an elastase [11] and colla-
genase activator [12], Wang et al. [13] suggested 
that cathepsin G promotes early atherogenesis 
through its elastinolytic activity, but at the same 
time suppresses late progression of atherosclero-
sis. In their study, patients with atherosclerosis 
had significantly reduced plasma levels of cathep-
sin G that were in negative correlation with total 
cholesterol and low density lipoprotein (LDL), but 
not high density lipoprotein (HDL) or triglycerides, 
suggesting a role of cathepsin G in degradation of 
LDL without affecting HDL or triglycerides [13].
A carboxypeptidase A3 (CPA3) is a zinc 
metalloprotease that is released from MCs and 
basophils as well. This enzyme degrades pro-
teins and peptides, including the apolipoprotein B; 
a component of LDL particles [14]. Upon MC acti-
vation and degranulation, CPA3 with the chymases 
and tryptases interacts with heparin proteoglycans 
[15]. It was shown to play a role in the inactivation 
of endothelin [16, 17] and degradation of angioten-
sin II [18], which suggests its antihypertensive 
activity.
The aim of the study was to check if a concen-
tration of MC derived proteases is elevated in sera 
of patients with different extensions of CAD, and 
thus to assess the role of MC in its pathogenesis. 
Methods
This was a prospective and single-center 
study. The study was conducted according to the 
Declaration of Helsinki and the protocol was re-
viewed and approved by the local ethics committee. 
All patients gave written informed consent.
Patients
Between November 2012 and May 2013, 44 
consecutive patients were prospectively screened 
who underwent diagnostic coronary angiography 
because of non-ST-segment elevation myocardial 
infarction (NSTEMI) or stable angina with a posi-
tive stress test. All the procedures were performed 
at the Department of Invasive Cardiology, Pomera-
nian Cardiology Centers, Wejherowo, Poland. Pa-
tients with renal failure, malignancy, and acute or 
chronic inflammatory disease were excluded from 
the study. Finally, 44 patients (23 NSTEMI and 
21 with stable angina) were included. Complete 
demographic and clinical data were obtained. Ac-
cordingly to the extension of CAD, patients were 
divided into two groups: subjects with one vessel 
CAD and those with two or three vessel CAD.
Blood sampling and laboratory tests
The blood samples were obtained after punc-
ture of a radial or a femoral artery and they were 
drawn from the vascular sheath during a coronary 
angiography.
Then, blood samples were centrifuged at 
1000 × g for 15 min to obtain serum. Subsequently, 
standard clinical parameters were measured and 
the remaining serum was apportioned into 0.5 mL 
aliquots, and stored at –80°C until analysis of CPA3, 
cathepsin G and chymase 1.
Measurement of CPA3, cathepsin G  
and chymase 1
Carboxypeptidase A3, cathepsin G and chy-
mase 1 concentrations were measured with ELISA 
(Cloud-Clone Corp., Houston, TX, USA) according 
to manufacturer instructions. The lower limit of 
682 www.cardiologyjournal.org
Cardiology Journal 2019, Vol. 26, No. 6
detection of CPA3, cathepsin G and chymase 1 
was < 3.0 pg/mL, < 0.065 ng/mL and < 13.5 pg/mL, 
respectively. Protein concentration was measured 
spectrophotometrically (Perkin Elmer VICTOR X4) 
at a wavelength of 450 ± 10 nm and was deter- 
mined by comparing the O.D. of samples to 
a standard curve.
Statistical analysis
The results are expressed as mean ± stand-
ard deviation. Comparisons between groups were 
performed using the t-Student test for continuous 
variables and c2 test for categorical variables. Wizard 
Statistics 1.8.16 software was used for analysis, p-va- 
lue < 0.05 was considered statistically significant.
Table 1. Demographic and biochemical data of 44 patients with significant coronary artery disease 
(CAD) according to the extension of CAD.
1 vessel CAD (n = 11) 2–3 vessel CAD (n = 33) P
Age [years] 68.3 ± 7.1 67.5 ± 2.6 0.7
Male/female 5/6 19/14 0.5
Body mass index [kg/m2] 30.7 ± 3.7 29.9 ± 1.5 0.6
Total cholesterol [mg/dL] 220.1 ± 48.1 171.3 ± 17 0.01
LDL cholesterol [mg/dL] 158.6 ± 46.8 98.4 ± 16 0.002
HDL cholesterol [mg/dL] 45.7 ± 9.3 44.6 ± 4.2 0.8
Serum creatinine [mg/dL] 1.7 ± 1.3 1.2 ± 0.1 0.1
eGFR 45.9 ± 11.4 53.5 ± 4.4 0.1
LVEF [%] 48.2 ± 5.5 47.6 ± 4.3 0.9
Arterial hypertension 11 13 0.2
Diabetes 4 15 0.6
History of previous MI 2 24 0.005
History of stroke/TIA 3 7 0.7
Current smoker 4 18 0.7
eGFR — estimated glomerular filtration rate; HDL — high density lipoprotein; LDL — low density lipoprotein; LVEF — left ventricular ejection 
fraction; MI — myocardial infarction; TIA — transient ischemic attack
Table 2. Demographic, biochemical and clinical data of 23 patients with non-ST-elevation myocardial 
infarction (NSTEMI) and 21 patients with stable coronary artery disease (CAD).
NSTEMI (n = 23) Stable CAD (n = 21) P
Age [years] 68.5 ± 3.8 66.8 ± 3.3 0.5
Body mass index [kg/m2] 30 ± 1.7 30.3 ± 2.3 0.8
Total cholesterol [mg/dL] 198.1 ± 28 167.5 ± 20.9 0.08
LDL cholesterol [mg/dL] 124.9 ± 27.3 100.9 ± 22.5 0.2
HDL cholesterol [mg/dL] 44.3 ± 5.3 45.6 ± 5.6 0.7
Serum creatinine [mg/dL] 1.5 ± 0.6 1.1 ± 0.1 0.2
eGFR 47.3 ± 6.6 56.4 ± 4.8 0.03
CRP 33.2 ± 25.6 5.3 ± 2.8 0.03
Arterial hypertension 21 18 0.5
Diabetes 9 10 0.6
History of previous MI 7 17 0.001
History of stroke/TIA 3 0 0.09
Current smoker 6 4 0.6
3 vessel CAD/1–2 vessel CAD 3/20 9/12 0.03
LVEF [%] 45.9 ± 4.2 49.7 ± 5.8 0.3
eGFR — estimated glomerular filtration rate; CRP — C-reactive protein; HDL — high density lipoprotein; LDL — low density lipoprotein;  
LVEF — left ventricular ejection fraction; MI — myocardial infarction; TIA — transient ischemic attack
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Results
The demographic and biochemical data of 44 pa-
tients with significant CAD are presented in Table 1. 
Patients with more advanced CAD had more often 
had a history of previous myocardial infarction (MI).
The major clinical and biochemical data of 23 
NSTEMI patients were compared to subjects with 
stable CAD are listed in Table 2. Patients with 
stable CAD had more often had a history of MI 
in the past and presented more often with three 
vessel CAD compared to NSTEMI patients. On 
the other hand, subjects with NSTEMI had sig-
nificantly higher levels of C-reactive protein and 
lower glomerular filtration rate.
Patients with one vessel CAD presented 
a significantly higher level of carboxypeptidase 
than those with more advanced CAD. Neither the 
cathepsin G nor chymase differed between the two 
groups (Fig. 1).
Significantly lower levels of cathepsin G were 
observed among patients with CAD and hyperten-
Figure 1. The differences in serum concentrations of carboxypeptidase A3 (pg/mL), chymase 1 (pg/mL) and cathepsin G 
(ng/mL) in patients with single vessel coronary artery disease (CAD) and 2 or3 vessel CAD. 
Figure 2. The differences in serum concentrations of carboxypeptidase A3 (pg/mL), chymase 1 (pg/mL) and cathepsin G 
(ng/ml) among patients with or without hypertension.
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sion as compared with normotensive CAD subjects 
(Fig. 2). Lower serum concentrations of cathepsin G 
in individuals with CAD were also associated with 
smoking (Fig. 3).
There were no statistically significant differ-
ences in levels of any protease between patients 
with stable CAD and those with NSTEMI (Fig. 4). 
Discussion 
Mast cells have been extensively investigated 
in the context of hypersensitivity [19] and little is 
known about their influence on the human body 
apart from allergic inflammation. However, in the 
present study it was shown that serum concentra-
tion of MC derived enzyme CPA3 was decreased 
in patients with more advanced CAD. In addition, 
higher levels of cathepsin G were found in nor-
motensive CAD patients and in those who were 
non-smokers. This data has shed new light on MC 
and the role of their activation in cardiovascular 
diseases. 
Previously, Xiang et al. [20] reported increased 
chymase concentration in patients with MI. How-
Figure 3. The differences in serum concentrations of carboxypeptidase A3 (pg/mL), chymase 1 (pg/mL) and cathepsin G 
(ng/ml) among patients with coronary artery disease (CAD) according to their smoking status.
Figure 4. The differences in serum concentrations of carboxypeptidase A3 (pg/mL), chymase 1 (pg/mL) and cathepsin G 
(ng/ml) in patients with stable coronary artery disease (CAD) and non-ST-segment elevation myocardial infarction 
(NSTEMI); AMI — acute myocardial infarction.
Carboxypeptidase A3
by smoking status
Cahthepsin G
by smoking status
Chymase 1
by smoking status
Non-smoker
Non-smoker
Non-smoker
Current smoker
Current smoker
Current smoker
p = 0.2
p = 0.02
p = 0.6
0
0
02000
2 4
5004000
6
10006000
10 12 14
1500 2000
3196.703 ± 499.942
5.811 ± 1.241
939.137 ± 188.543
2474.093 ± 973.152
3.057 ± 1.236
832.481 ± 427.601
Carboxypeptidase A3
by AMI
Cahthepsin G
by AMI
Chymase 1
by AMI
Stable CAD
Stable CAD
Stable CAD
NSTEMI
NSTEMI
NSTEMI
p = 0.4
p = 0.5
p = 0.5
0
0
02000
2 4
5004000
6 8
10006000
10 12 14
1500 2000
2807.101 ± 557.452
4.82 ± 1.374
996.854 ± 273.553
3169.216 ± 682.564
5.438 ± 1.575
881.359 ± 202.058
www.cardiologyjournal.org 685
Łukasz Lewicki et al., Mast cells in coronary artery disease
ever, there is no data concerning a possible asso-
ciation of carboxypeptidase and presence of CAD. 
In the current study, significantly higher levels of 
CPA3 were observed in patients with angiographi-
cally confirmed single vessel CAD as compared 
with subjects with advanced two or three vessel 
disease. 
Carboxypeptidase A3 and chymase 1 play 
a key role in the formation as well as degradation of 
angiotensin II [18]. Whereas chymase is the main 
tissue converter of angiotensin I to angiotensin II, 
CPA3 creates peptides Ang-(1–9) and Ang-(1–7) 
that antagonize angiotensin II [18]. The peptide 
angiotensin II is not only a strong vasoconstrictor, 
but it also can promote atherosclerosis via several 
biologic activities such as: an increased expression 
of adhesion molecules on endothelial cells, activa-
tion of macrophages and upregulation of matrix 
metalloproteinases and proinflammatory cytokines 
[21, 22]. Therefore, as an indirect antagonist of 
angiotensin II, CPA3 exerts a protective effect 
in CAD. CPA3 was also found to degrade another 
vasoconstrictor — endothelin-1 and was found to 
play a cardioprotective effect during ischemia-rep-
erfusion injury [23]. In addition, the present study 
revealed that lower serum concentration of the 
peptide was characteristic for patients with more 
advanced CAD and also for those who were active 
smokers. As smoking is one of the most widely 
known risk factors of cardiovascular diseases [24], 
this data suggests that one of the mechanisms of 
the deleterious impact of smoking on blood vessels 
might be an inhibitor of CPA3 production. Thus, all 
these data together confirms a protective effect of 
this enzyme in CAD. 
When NSTEMI patients were compared with 
those having stable CAD, nosignificant differences 
were found in the levels of any of the proteases 
studied. Previously Xiang et al. [20] reported that 
serum chymase levels were higher in patients with 
AMI compared to subjects with stable CAD, however 
this difference was not statistically significant [20]. 
The lack of significant differences in serum levels of 
chymase between patients with MI and stable CAD in 
the cited study and chymase and carboxypeptidase of 
the present research may reflect the fact that an un-
derlying mechanism of angiotensin II regulation influ-
ences chronic atherosclerosis rather than a formation 
of unstable coronary plaque and consequently AMI.
The concentration of cathepsin G was signifi-
cantly lower in current smokers and hypertensive 
patients than in non-smokers and normotensive in-
dividuals, respectively. Wang et al. [13] has shown, 
that cathepsin G promoted early atherogenesis 
through its elastinolytic activity, but on the other 
hand it suppressed late progression of atheroscle-
rosis by degrading LDL. In their study patients with 
CAD were characterized with significantly lower 
levels of cathepsin G and higher levels of LDL, than 
individuals without CAD [13]. In the present study, 
decreased serum concentration of cathepsin G 
in CAD patients was associated with tabacco 
smoking or hypertension. Cathepsin G was found 
to exert an anti-inflammatory effect by reducing 
biological activity of inflammatory cytokines [25]. 
As both hypertension and smoking are associated 
with inflammation and increased production of 
pro-inflammatory cytokines [26], lower levels of 
protease in these patients may reflect an exhaus-
tion of its production in chronic inflammation. 
Conclusions
1. Decreased serum concentration of CPA3 is 
a hallmark of more advanced CAD.
2. Lower serum levels of CPA3 and catepsin G 
are associated with risk factors of blood vessel 
damage suggesting a protective role of these 
enzymes in CAD. 
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